|
CAD106
|
Novartis (Basel, Switzerland)
|
Aβ1–6/bacteriophage Qβ coat protein
|
i.m./s.c.
|
2
|
Mild-to-moderate AD
|
|
ACC-001 (vanutide cridificar)
|
Pfizer (New York, USA)/Janssen Research & Development, LLC (Raritan and Titusville, NJ, USA)
|
Aβ1–7/nontoxic diphtheria toxin (CRM197)/Qs21 adjuvant
|
i.m.
|
2
|
Mild-to-moderate AD, early AD
|
|
AD02
|
AFFiRiS (Vienna, Austria)/GlaxoSmithKline (Brentford, UK)
|
Aβ1–6 mimetic/keyhole limpet hemocyanin/aluminum adjuvant
|
s.c.
|
2
|
Mild-to-moderate AD, early AD
|
|
ACI-24
|
AC Immune (Lausanne, Switzerland)
|
Tetra-palmitoylated Aβ1– 15/reconstituted in liposome
|
s.c.
|
1/2
|
Mild-to-moderate AD
|
|
V950
|
Merck & Co. (Whitehouse Station, NJ, USA)
|
Multivalent Aβ peptide/ISCOMATRIX™ adjuvant
|
i.m.
|
1 (discontinued)
|
Mild-to-moderate AD
|
|
UB-311
|
United Biochemical, Inc. (Hauppauge, NY, USA)
|
Two UBITh® synthetic peptides coupled to Aβ1–14 peptide/CpG oligonucleotide
|
i.m.
|
2
|
Mild-to-moderate AD
|
|
Lu AF20513
|
Lundbeck A/S (Valby, Denmark)
|
Aβ1– 12 peptide replaced with two foreign T-helper epitopes from tetanus toxoid
|
N/A
|
Preclinical
|
Early AD
|
